These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis.
    Author: Nadiminti U, Arbiser JL.
    Journal: J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):17-9. PubMed ID: 15692505.
    Abstract:
    Dermatomyositis is an autoimmune condition that results in significant morbidity and mortality through effects on muscle and skin. Corticosteroids are the mainstay of therapy of dermatomyositis, and severe morbidity and mortality occurs in part through the known long-term side effects of chronic steroid use. In addition, dermatomyositis is commonly associated with underlying malignancy, and high-dose steroids may adversely impair treatment of these malignancies. We describe the first use of rapamycin in a young patient with dermatomyositis.
    [Abstract] [Full Text] [Related] [New Search]